ASHP Therapeutic Position Statement on the Cessation of Tobacco Use

Hudmon, Karen Suchanek; Corelli, Robin L.

doi:10.2146/ajhp070303

Cited by 16 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Services delivered by pharmacists can range from simple advice about the importance of smoking cessation to give advice on cessation medication and more intensive behavioral approaches. At present, an involvement of pharmacists in tobacco cessation was encouraged by several organizations including National Health Service (NHS), the International Pharmaceutical Federation (FIP), American Society of Health System Pharmacy (ASHP) (McRobbie and McEwen, 2005, Siiskonen, September 2004, Hudmon and Corelli, 2009). However, barriers of pharmacist to provide smoking cessation counseling are lack of time and lack of knowledge and skill (Goniewicz et al, 2010, El Hajj et al, 2012.…”

Section: Effectiveness Of Tobacco Education For Pharmacy Students In mentioning

confidence: 99%

Effectiveness of Tobacco Education for Pharmacy Students in Indonesia

Kristina¹,

Thavorncharoensap²,

Pongcharoensuk³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Effectiveness Of Tobacco Education For Pharmacy Students In mentioning

confidence: 99%

Effectiveness of Tobacco Education for Pharmacy Students in Indonesia

Kristina¹,

Thavorncharoensap²,

Pongcharoensuk³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…NRT is used primarily to decrease symptoms of withdrawal while the smoker is gradually weaned from the physical addiction. Unlike the inhalation of nicotine contained in smoke, which allows for nearly immediate effects on receptors and virtually instant satisfaction for the smoker, replacement therapies have a slower onset, allowing the user to become less accustomed to immediate reinforcement 8. By decreasing withdrawal symptoms, replacement therapy allows the smoker to focus on necessary changes in behavior.…”

Section: Treatment Options For Smoking Cessationmentioning

confidence: 99%

“…An early alert was initially put forth in November 2007. Shortly thereafter, a public health advisory was sent out by the FDA warning practitioners about concerns over neuropsychiatric symptoms in patients using varenicline 8. Symptoms that had been observed included behavioral changes, mood disorders, generalized agitation, and in some cases, suicidal ideation.…”

Section: Patient-focused Outcomes and Safetymentioning

confidence: 99%

Smoking cessation: an economic analysis and review of varenicline

Faulkner¹

2009

CEOR

View full text Add to dashboard Cite

Despite efforts to decrease tobacco use, smoking continues to be a leading cause of preventable morbidity and premature death. The associated economic burden is substantial, both in the form of direct costs (healthcare expenditures) and indirect costs (lost productivity), regardless of whether the burden is assessed from the standpoint of an employer, a health plan, or society as a whole. Cessation programs are considered among the most cost-effective in healthcare, and are often used as a benchmark for other medical interventions. This analysis specifically considers the cost-effectiveness of varenicline, a novel α4β2 partial agonist used for smoking cessation, in comparison to other approved therapies. Clinical trial data have demonstrated that varenicline has the ability to decrease cravings and withdrawal symptoms, and lessen positive reinforcement associated with smoking. Varenicline’s novel mechanism has translated into superior efficacy in comparison to other available therapies. For this reason, despite an initial cost that typically exceeds that of other medications, varenicline is a cost-effective option for smoking cessation.

show abstract

“…As per the ASHP statement, these interventions should address five key elements of comprehensive tobacco cessation counseling (the 5 As): (1) asking patients about tobacco use, (2) advising users to quit, (3) assessing their readiness to quit, (4) assisting them with quitting using behavior modification and smoking cessation medications, and (5) arranging follow-up care. If comprehensive tobacco-cessation counseling cannot be provided because of time constraints or practice site logistics, pharmacists can use a truncated 5 A model whereby they ask about tobacco use, advise tobacco users to quit, and then refer patients to smoking cessation providers or programs [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Assessing the effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: study protocol for a randomized controlled trial

Hajj

Kheir

Mulla

et al. 2015

Trials

View full text Add to dashboard Cite

BackgroundIt had been reported that up to 37% of the adult male population smokes cigarettes in Qatar. The Global Youth Tobacco Survey also stated that 13.4% of male school students aged 13 to 15 years in Qatar smoke cigarettes. Smoking cessation is key to reducing smoking-related diseases and deaths. Healthcare providers are in an ideal position to encourage smoking cessation. Pharmacists are the most accessible healthcare providers and are uniquely situated to initiate behavior change among patients. Many studies have shown that pharmacists can be successful in helping patients quit smoking. Studies demonstrating the effectiveness of pharmacist-delivered smoking cessation programs are lacking in Qatar. This proposal aims to test the effect of a structured smoking cessation program delivered by trained ambulatory pharmacists in Qatar.Methods/DesignA prospective, randomized, controlled trial is conducted at eight ambulatory pharmacies in Qatar. Participants are randomly assigned to receive an at least four-session face-to-face structured patient-specific smoking cessation program conducted by the pharmacist or 5 to 10 min of unstructured brief smoking cessation advice (emulating current practice) given by the pharmacist. Both groups are offered nicotine replacement therapy if feasible. The primary outcome of smoking cessation will be confirmed by an exhaled carbon monoxide test at 12 months. Secondary outcomes constitute quality-of-life adjustment as well as cost analysis of program resources consumed, including per case and patient outcome.DiscussionIf proven to be effective, this smoking cessation program will be considered as a model that Qatar and the region can apply to decrease the smoking burden.Trial registrationClinical Trials NCT02123329.

show abstract

ASHP Therapeutic Position Statement on the Cessation of Tobacco Use

Cited by 16 publications

References 44 publications

Effectiveness of Tobacco Education for Pharmacy Students in Indonesia

Effectiveness of Tobacco Education for Pharmacy Students in Indonesia

Smoking cessation: an economic analysis and review of varenicline

Assessing the effectiveness of a pharmacist-delivered smoking cessation program in the State of Qatar: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About